Two District Courts Address Challenges to EpiPen Manufacturer Rebates | Patterson Belknap Webb & Tyler LLP
To embed, copy and paste the code into your website or blog: Recent decisions in two different antitrust cases involving price increases and marketing practices for the EpiPen address a relationship solidly embedded in the current architecture of pharmaceutical drug markets: payments between manufacturers and pharmacy benefit managers (“PBMs”) hired by health plans to manage prescription drug programs. These new rulings suggest that while certain manufacturer rebates have come under increased scrutiny in recent years, the standard industry practice remains on firm footing. In general, h...
Source: jdsupra.com